- Oral presentation
- Open Access
Tuberculosis reactivation during novel, biologic therapy
BMC Infectious Diseasesvolume 13, Article number: O25 (2013)
Biologic immunotherapy such as anti-TNF or monoclonal antibody against CD20 protein revolutionized the treatment of autoimmune diseases. Unfortunately, the patients receiving this therapy are at higher risk for bacterial or fungal infections, and at risk for reactivation of latent viral infections and latent tuberculosis. We present a series of patients receiving biologic therapy, admitted in the Adults 3 Department of the National Institute for Infectious Diseases “Prof. Dr. Matei Balş” for prolonged fever.
All of the patients were diagnosed with tuberculosis. One patient was treated with rituximab for non-Hodgkin lymphoma, 2 patients were treated with infliximab for rheumatoid arthritis, one patient was treated with infliximab for ankylosing spondylitis and one patient was treated with etanercept for severe psoriasis. Two of the patients were diagnosed with pulmonary tuberculosis and for three patients the localization of tuberculosis was not identified. All of the patients had quantiferon TB gold positive. Only one of the patients had positive microbiologic tests for tuberculosis. All of the patients had a good therapeutic response after anti-tuberculous therapy. None of the patients had been tested for latent tuberculosis prior to initiation of biologic therapy.
We emphasize the importance of anti-tuberculosis prophylaxis for patients diagnosed with latent tuberculosis, before the start of biologic therapy. The diagnosis of latent tuberculosis remains an important issue especially in a country with high incidence of tuberculosis.